Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression… Read More
Drug Discovery Spending – A Year In Review By Isaac Meek Drug In 2003, the research products market reported revenues of $23 billion, with a 7.5% growth rate over 2002. Although there are many consumers in this market, by far the greatest are drug discovery research groups. Read More
Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library By Andrea Kroenke, Anne Grabner, Dr Michael Hannus, Dr Christoph Sachse, Dr David Dorris and Dr Christophe Echeverri Libraries of siRNAs directed against predefined subsets of genes now offer the capacity… Read More
Role of image informatics in accelerating drug discovery and development By Robert Dunkle There is a new category of informatics that is proving itself essential to the acceleration of drug discovery and development. Image informatics is the systematic use of image data as a means to help interpret… Read More
New Flash Imagers: Facilitating higher throughput functional GPCR assays By Dr John Comley The recent availability of tailored automation solutions that combine liquid handling at the reading position with the latest innovations in low light imaging technology are providing screeners with new tools for the measurement of… Read More
Accommodating cells in HTS By Sandra Fox High Throughput Screening has become an important and integrated part of drug discovery at most pharmaceutical and many biotechnology companies worldwide, and is now entrenched in the drug discovery process. To produce high quality leads, centralised HTS… Read More
SCAVENGER strategies in organic synthesis – Part One By Professor Peter Wipf and Dr Claire M. Coleman Over the past 20 years combinatorial chemistry has proved to be an important tool for the generation of large numbers of compounds required for drug discovery programmes. This two-part article… Read More
By Dr Paul Charlton To negotiate the optimum terms and conditions for deals which ensure a truly ‘wise agreement’, one that is mutually beneficial, realistically implementable, profitable and can withstand the inevitable knocks and trials that present themselves at usually the most inconvenient of moments should… Read More
By Tim Ward Cell culture is and has historically been an essential component of the drug discovery toolbox. Cell culture provides the proteins, membrane preparations and other raw materials required for biological research. In recent years, with the emergence of high-throughput… Read More
Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical… Read More
PATCHERS vs SCREENERS: divergent opinion on high throughput electro-physiology By Dr John Comley The prospect of enabling higher throughput electro-physiology (patch-clamping) has created much expectation from scientists within the ion channel community. Yet there are opposing views among traditional electro-physiologists and screeners as to the needed specification and… Read More
By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease… Read More
The Industrial Evolution of Screening Infrastructure By Chris Molloy Industrialisation of screening depends upon the use of a stable,mature infrastructure. According to a recent Boston Consulting Group report, a pharmaceutical company needs to spend 900 million ($810 million) on R&D to bring a product to market. Read More
Synthetic approaches to rational drug design – A changing landscape By Dr Shubh Sharma and Dr Carl Spana It is becoming clearer that newer synthetic approaches for rational drug design may hold the promise of taking us closer to industrialising drug discovery while, at the same time, overcoming… Read More
ASSAY INTERFERENCE – A limiting factor in HTS? By Dr John Comley With current HTS focused on better quality hits, the necessity to differentiate between true and false results puts increasing emphasis on the robustness of the assay technology. This article explores the… Read More
The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components,… Read More